<DOC>
	<DOCNO>NCT01474083</DOCNO>
	<brief_summary>The purpose trial study drug level biomarkers body safety investigational drug ( GK1-399 ) patient Type 2 diabetes . Patients study receive placebo 1 week follow 1 4 treatment 6 week . One 4 treatment placebo , contain active ingredient . The study participation include in-patient out-patient day .</brief_summary>
	<brief_title>A 6 Week Pharmacokinetics , Pharmacodynamics , Safety Tolerability GK1-399 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Be male female , age 18 75 year screen . Have diagnosis Type 2 Diabetes Mellitus ( T2DM ) On stable dose background medication treatment diabetes Body Mass Index ( BMI ) 2040 kg/m2 ( inclusive ) Subjects type 1 diabetes , heart attack stroke past 6 month , uncontrolled blood pressure , significant kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>